GH — Guardant Health Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Data provided bySource: Twelve DataPrice data
- Price
- $143.28
- YTD price return
- +40.28%
- YTD total return
- +40.28%
- Market cap
- 19.4B
- Enterprise value
- 20B
- Shares outstanding
- 135.3M
- 52W low
- $74.55
- 52W high
- $191.05
- From 52W high
- -25.00%
- From 52W low
- +92.19%
- 52W range
- 59%$74.55–$191
- Beta
- 1.57
Volume
- Rel volume
- 0.94×
- 30D volume
- 2.1M
- 30D $ vol
- 337.1M
Insider trading
- Insider net 1W
- −$28K
- Insider net 1M
- −$28K
- Insider net 3M
- −$9.7M
- Insider net 1Y
- −$129.2M
Form 4 transactions by trade date, as filed; latest on file 2026-11-16.
Fundamentals
- Sales (ttm)
- 1.3B
- Sales/share
- $9.45
- EPS (ttm)
- -$3.68
- FCF (ttm)
- -232.1M
- FCF/share
- -$1.72
- Book value/share
- -$2.04
- Net margin
- -37.93%
- ROA
- -25.72%
- Current ratio
- 3.60
Growth (CAGR, ttm) · 10Y
- Sales
- +41.73%+33.63%+30.05%+49.58%
- Shares
- +7.34%+4.66%+5.88%n/a
Per-share growth (CAGR, ttm) · 10Y
- Sales/share
- +32.04%+27.68%+22.82%n/a
- Price
- +48.55%+83.23%+6.35%n/a
- Total return
- +48.55%+83.23%+6.35%n/a
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- -38.9×
- Fwd P/E
- -547.2×
- P/S (ttm)
- 15.2×
- P/B (mrq)
- -70.3×
- EV/Sales (ttm)
- 15.7×
- FCF yield (ttm)
- -1.20%
- Buyback yield (realized, 1y)
- -7.34%
- Shareholder yield (realized, 1y)
- -7.34%
- Buyback yield (cash, ttm)
- -1.33%
- Shareholder yield (cash, ttm)
- -1.33%
Vs own 10Y history
- P/S
- 50th
- P/B
- 97th
Bar = where today’s multiple sits in GH’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-17#
Data provided bySource: Twelve DataFundamentals#
Operating income
5Y n/m5Y n/mYoY n/mEPS (diluted)
5Y n/m5Y n/mYoY n/mFree cash flow
5Y n/m5Y n/mYoY n/mTTM: operating cash flow −$173.5M, capex −$58.7M
Q3 2026: operating cash flow −$23.7M, capex −$13.5M
Shares (diluted)
5Y +28.6%5Y +28.6%YoY +7.7%Net income
5Y n/m5Y n/mYoY n/mAbout Guardant Health#
Data provided bySource: Twelve DataGuardant Health, Inc. is a precision oncology company that develops blood- and tissue-based diagnostic tests, data solutions, and analytics for cancer care. Its offerings support multiple stages of the oncology pathway, including screening for colorectal cancer, molecular profiling of tumors, treatment selection, monitoring for residual disease and recurrence, and research into tumor biology and therapeutic response. Products such as Guardant360, Guardant Reveal, Guardant360 Tissue, and Shield provide clinicians and researchers with genomic, epigenomic, transcriptomic, and circulating tumor DNA insights. The company also serves biopharmaceutical organizations through companion diagnostic development, clinical testing services, technology licensing, and real-world data solutions. Its software and data platforms help connect molecular findings with clinical outcomes and relevant research opportunities. Headquartered in Palo Alto, California, Guardant Health, Inc. operates across healthcare, biotechnology, clinical diagnostics, and biopharmaceutical markets, contributing to the broader use of precision medicine in cancer prevention, diagnosis, treatment, and monitoring.
Palo Alto, CA·2,490 employees·Diagnostics & Research·guardanthealth.com·As of Oct 28, 2026
Recent filings#
- Nov 168-K · Guardant Health Announces Proposed $500.0 Million Offering of Convertible Senior Notes Due 2032
- Nov 5Earnings · Earnings release — EPS −$0.93 vs −$0.68 est. (−36.8%); revenue $361.0M (+36% y/y) 1.7%
- Nov 38-K · Kevin Sayer Joins Guardant Health Board of Directors
- Sep 16Insider sale · Krognes Steve E. (Director) sold 6,674 shares for $1.2M at $174.46–$177.48
- Sep 15Insider sale · Chudova Darya (Chief Technology Officer) sold 7,738 shares for $1.4M at $178.00
ETFs holding GH#
20 of the 193 ETFs ChartRow carries live hold GH. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| VBK | Vanguard Small-Cap Growth ETF | 0.5% |
| IWP | iShares Russell Mid-Cap Growth ETF | 0.5% |
| VHT | Vanguard Health Care ETF | 0.3% |
| VXF | Vanguard Extended Market ETF | 0.2% |
| VB | Vanguard Small-Cap ETF | 0.2% |
| IWR | iShares Russell Midcap ETF | 0.1% |
| VONG | Vanguard Russell 1000 Growth ETF | 0.1% |
| IWF | iShares Russell 1000 Growth ETF | 0.1% |
Related Healthcare#
Data provided bySource: Twelve Data| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +12.61% | -1.13% |
| JNJ | Johnson & Johnson | +9.05% | -1.36% |
| ABBV | AbbVie Inc. | +2.59% | -0.59% |
| MRK | Merck & Co. Inc. | -1.77% | -0.75% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | -2.93% | -5.42% |
| NVS | Novartis AG | +5.65% | -0.67% |
| TMO | Thermo Fisher Scientific Inc. | -0.47% | -0.66% |
| AMGN | Amgen Inc. | +5.88% | -0.95% |
